Abstract Furmonertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has demonstrated systemic and central nervous system (CNS) antitumor activity in patients with EGFR-mutant non-small cell lung cancer (NSCLC); however, evidence supporting its use in patients with diffuse...

AbstractBackground and Objectives In clinical trials, osimertinib combined with chemotherapy has demonstrated improved efficacy in patients with advanced epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer. However, the projected long-term outcomes and the associated cost effectiveness compared to osimertinib monotherapy...

Abstract Estimated glomerular filtration rate (eGFR) slope, which quantifies the annual change in kidney function using longitudinal measurements of eGFR, has emerged as a critical surrogate endpoint for chronic kidney disease progression in clinical trials. Accordingly, there is an increasing...

With the increasing detection of multiple primary pulmonary nodules, accurately distinguishing between multiple primary lung cancers and intrapulmonary metas Case report A 71-year-old Asian female non-smoker presented with a non-productive cough and occasional bloody sputum of unknown cause, which did...

Abstract Chronic kidney disease (CKD) is a global health challenge characterized by progressive kidney function decline, often culminating in end-stage kidney disease (ESKD) and increased mortality. To address the limitations such as the extended trial follow-up necessitated by the low...

Data presented at 16th World ADC London Summit with lead programme in colorectal cancer highlight the promise of Promatix’s proteomics-based platform to optimise cis-bispecific antibody-drug conjugate (ADC) discovery and designDual-antigen targeting strategy utilises hybrid avidity-gated binding to improve tumour cell...